Precision immunotherapy tailored to patients with sepsis can improve their outcomes compared with placebo treatment, according to a trial conducted at 33 intensive care units in six countries.

The approach, outlined in JAMA , could help clinicians design targeted interventions in which sepsis patients are treated according to their distinct immune responses.

Personalizing immunotherapy according to immune profile was better at reducing dysfunction in the vital organs of these critically ill patients versus placebo in the ImmunoSep trial.

Nearly twice as many patients receiving immunotherapy based on biomarkers achieved the primary endpoint threshold for improvement in organ function versus placebo.

“Among patients with sepsis, precision immunotherapy targeting macrophage activation

See Full Page